Rashmi K Murthy, MD, MBE

Peer-Reviewed Articles

1. Akkoc Mustafayev FN, Shukla MA, Lanier A, Milton DR, Gutierrez AM, Gruschkus SK, Lewis JE, RK <, Arun BK. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer 130(9):1600-1608, 2024. e-Pub 2023. PMID: 38100492.
2. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
3. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
4. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers 2023 15:3275, 2023. PMID: None.
5. Murthy RK, Kahn BJ, Zhang C, Chen SC. Stratifying clinical complexity of dermatology outpatient visits: Validation of a pilot instrument. J Am Acad Dermatol 88(5):e251-e258, 2023. e-Pub 2019. PMID: 30772335.
6. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2+ Metastatic Breast Cancer (HER2CLIMB) in Patients With Brain Metastases. JAMA Oncol 9(2):197-205, 2023. PMID: 36454580.
7. Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin Cancer Res 29(1):174-182, 2023. e-Pub 2022. PMID: 36074155.
8. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
9. Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, Gonzàlez Farré X, You B, Saura C, Kim SB, Osborne CR, Murthy RK, Gianni L, Takano T, Liu Y, Cathcart J, Lee C, Perrin C. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov 12(12):2754-2762, 2022. e-Pub 2022. PMID: 36255231.
10. Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy RK, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. NPJ Breast Cancer 8(1):128, 2022. e-Pub 2022. PMID: 36456573.
11. Conlin, A, Chun, BM, Borges, VF, Moxon, NM, Parris, HJ, Walker, L, Murthy, RK. Cutaneous responses in HER2+ metastatic breast cancer. Current Problems in Cancer: Case Reports 7, 2022. PMID: None.
12. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
13. Curigliano, G, Mueller, V, Borges, VF, Hamilton, E, Hurvitz, S, Loi, S, Murthy, RK, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, IE, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W, Winer, EP. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Annals of Oncology 33(3):321-329, 2022. PMID: 34954044.
14. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
15. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Reply to A. Pfob and C. Sidey-Gibbons. JCO Clin Cancer Inform 6(6):e2100171, 2022. PMID: 35175860.
16. Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Consortium IT, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF, Murthy, RK. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23(1):149-160, 2022. e-Pub 2021. PMID: 34902335.
17. Westin, SN, Labrie, M, Litton, J, Blucher, A, Fang, Y, Vellano, CP, Marszalek, JR, Feng, N, Ma, X, Creason, A, Fellman, B, Yuan, Y, Lee, S, Kim, T, Liu, J, Chelariu-Raicu, A, Chen, TH, Kabil, N, Soliman, PT, Frumovitz, M, Schmeler, KM, Jazaeri, AA, Lu, KH, Murthy, RK, Meyer, LA, Sun, CC, Sood, AK, Coleman, R, Mills, GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research 27(23):6354-6365, 2021. PMID: 34518313.
18. Labrie M, Litton J, Yuan Y, Fellman B, Coleman R, Soliman P, Frumovitz M, Jazaeri A, Murthy RK, Lu K, Schmeler K, Blucher A, Lee S, Fang Y, Vellano C, Marsialek J, Feng N, Ma X, Creason A, Kim T, Liu J, Chelarbe-Raicu A, Meyer L, Sun C, Sood A, Chen T, Kabil N, Mills G. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical Cancer Research, 2021. e-Pub 2021. PMID: None.
19. Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol 7(11):1654-1663, 2021. e-Pub 2021. PMID: 34529000.
20. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 2021. PMID: 34351787.
21. Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, Fan C, Soloway MG, Spears PA, Jefferys S, Parker JS, Gallagher KK, Forero-Torres A, Krop IE, Thompson AM, Murthy RK, Gatza ML, Perou CM, Earp HS, Carey LA, Johnson GL. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. NPJ Breast Cancer 7(1):51, 2021. e-Pub 2021. PMID: 33980863.
22. Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol 225:108679, 2021. e-Pub 2021. PMID: 33485895.
23. Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, Fan C, Soloway MG, Spears PA, Jeffrys SR, Parker JS, Gallagher K, Forrero A, Krop I, Thompson AM, Murthy RK, Gatza ML, Perou CM, Earp HS, Carey LA. FOXA1 is an adaptive response determinant of targeted therapy in HER2-positive breast cancer. Clincal Cancer Research 7(1), 2021. PMID: 33980863.
24. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Reply to T.J.A. Dekker. J Clin Oncol 38(28):JCO2001212, 2020. e-Pub 2020. PMID: 32658630.
25. Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol 38(23):JCO2000775, 2020. e-Pub 2020. PMID: 32468955.
26. Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ, Holmes JP, Peoples GE, Mittendorf EA. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients. Clin Cancer Res 26(11):2515-2523, 2020. e-Pub 2020. PMID: 32071118.
27. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol 38(17):JCO1902318, 2020. e-Pub 2020. PMID: 32058843.
28. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist 25(6):e909-e919, 2020. e-Pub 2020. PMID: 32003919.
29. Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy RK, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, Consortium I. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol 38(10):1059-1069, 2020. e-Pub 2019. PMID: 32031889.
30. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 382(7):597-609, 2020. e-Pub 2019. PMID: 31825569.
31. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38(5):JCO1901304, 2020. e-Pub 2019. PMID: 31461380.
32. Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat 176(1):227-234, 2019. e-Pub 2019. PMID: 30977027.
33. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
34. Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 20(6):816-826, 2019. e-Pub 2019. PMID: 31047803.
35. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski D, Layman RM, Booser D, Hatzis C, Valero V, Symmans WF. SET ER/PR: A Robust 18-Gene Predictor for Sensitivity to Endocrine Therapy for Metastatic Breast Cancer. NPJ Breast Cancer, 2019. PMID: None.
36. Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth A. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clin Immunol 201:48-54, 2019. e-Pub 2019. PMID: 30817999.
37. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2018. PMID: 30442682.
38. Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24(3):313-318, 2019. e-Pub 2018. PMID: 30139836.
39. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
40. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
41. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
42. Murthy RK, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. A Phase 1b Open-Label Study of Tucatinib Combined with Capecitabine and Trastuzumab in Advanced HER2+ Metastatic Breast Cancer with and without Brain Metastases. Lancet Oncology 19(7):880-888, 2018. e-Pub 2018. PMID: None.
43. Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw 16(5):518-524, 2018. PMID: 29752326.
44. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A Phase II Study of Tipifarnib and Gemcitabine in Metastatic Breast Cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
45. Litton, JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A Feasibility Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Germline BRCA Mutation Demonstrates Marked Activity. NPJ Breast Cancer 3(49), 2017. PMID: None.
46. Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res 23(14):3529-3536, 2017. e-Pub 2017. PMID: 28053022.
47. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2016. PMID: 27893038.
48. Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 116(4):509-514, 2017. e-Pub 2017. PMID: 28081544.
49. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367-74, 2016. e-Pub 2016. PMID: 27522517.
50. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy RK. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab. J Clin Oncol. e-Pub 2016. PMID: 27298406.
51. Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res 16(6):3414, 2014. e-Pub 2014. PMID: 25547133.
52. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 2014. e-Pub 2014. PMID: 24677057.
53. Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer 118(17):4098-104, 2012. e-Pub 2012. PMID: 22281842.
54. Kvale EA, Murthy RK, Taylor R, Lee JY, Nabors LB. Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer 17(7):793-9, 2009. e-Pub 2009. PMID: 19421789.
55. Murthy RK, O’Brien BJ, Berry DA, Singareeka-Raghavendra A, Monroe MG, Johnson J, White J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Riley K, Melisko M, Morikawa A, Ferguson SD, de Groot JF, Krop I, Valero V, Rimawi M, Wolff AC, Tripathy D, Lin NU, Stringer-Reasor E. Tucatinib-Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: TBCRC049 Phase 2 Non-Randomized Study Results. Neuro-Oncology. PMID: None.

Invited Articles

1. Murthy RK, Chavez-Macgregor M, Hortobagyi GN. Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. Current Breast Cancer Reports, 2018. PMID: None.
2. Murthy RK, Morrow PK, Theriault RL. Bone biology and the role of the RANK ligand pathway. Oncology (Williston Park) 23(14 Suppl 5):9-15, 2009. PMID: 20128323.

Other Articles

1. Murthy RK Financial Toxicity in Breast Cancer Patients Receiving Regional Nodal Irradiation: Variation by Cancer Subtype. The Breast None(None):None. PMID: None.
2. Curigliano, G, Mueller, V, Borges, VF, Hamilton, E, Hurvitz, S, Loi, S, Murthy, RK, Okines, A, Paplomata, E, Cameron, D, Carey, LA, Gelmon, K, Hortobagyi, GN, Krop, IE, Loibl, S, Pegram, M, Slamon, D, Ramos, J, Feng, W, Winer, EP Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB). Annals of Oncology 34(7):630, 2023. PMID: 36564285.
3. Pegram M, Pietras R, Dang CT, Murthy RK, Bachelot T, Janni W, Sharma P, Hamilton E, Saura C Evolving Perspectives on the Treatment of HR+/HER2+ Metastatic Breast Cancer. Ther Adv Med Oncol 15:17588359231187201, 2023. PMID: 37576607.
4. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer 6:11, 2020. PMID: 32219153.

Abstracts

1. Faiz S, Knox AS, Fellman BM, Jaumally BA, Pacheco GN, Das A, Mathew R, Murthy RK, Litton J, Balachandran DD, Bashoura L. Sleep Disturbances based on Patient Reported Outcomes in Patients with Breast Cancer. International Journal of the Science and Practice of Sleep Medicine None(None):None. e-Pub 2024. PMID: None.
2. O'Brien BJ, Murthy RK, Berry DA, Raghavendra AS, Gule-Monroe M, Johnson JM, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko ME, Morikawa A, Ferguson SD, de Groot JF, Krop IE, Valero V, Rimawi MF, Wolff AC, Tripathy D, Lin NU, Stringer-Reasor EM. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. ASCO, 2024. PMID: None.
3. Akkoc Mustafayev FN, Shukla MA, Lanier A, Milton DR, Gutierrez AM, Gruschkus SK, Lewis JE, Murthy RK, Arun BK. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer 130(9):1600-1608, 2024. PMID: 38100492.
4. Sammons S, Van Swearingen AED, Bagegni N, Moulton K, Threatt S, Jaggers D, Shea S, Lipp ES, Riley E, Jung SH, Broadwater G, Ross M, Strickland K, Beyer S, Conlin A, Morikawa A, Murthy RK, Anders CK. Trial in Progress: Secondary BRain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib (BRIDGET). ASCO, 2023. PMID: None.
5. Valero V, Mouabbi J, Alonzo H, Nwosu Ilheme A, Murthy RK, Huang Y, Qiao W, Patel M, Pohlmann PR, Rauch G, Checka C, Hunt K, Tripathy D, Meric-Bernstam F, Symmans F, Oncology Dept BM, Oncology Dept BM, Cancer Center TUOTMA, Therapeutics Department IC, Cancer Center TUOTMDA. Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (BC). ESMO 2023, 2023. PMID: None.
6. Waks AG, Shi R, Regan M, Dang C, Santa-Maria C, Westbrook K, Abramson V, Murthy RK, Nanda R, Rugo HS, Clark AS, Mainor C, Dees EC, Hoyos V, Miller K, Stringer-Reasor E, Hunter N, Oh SY, DeMeo M, Okpoebo A, Elias E, Kurt BB, Lin NU, Rimawi MF, Wolff AC, Mittendorf E, Goel S, Tolaney SM, Loi S, Krop IE. A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC). SABCS 2023, 2023. PMID: None.
7. Yam C, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser B, Buzdar A, Candelaria RP, Chen JJ, Clayborn A, Damodaran S, Ding QQ, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleeem S, Teshome M, Valero V, White J, Williams M, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch GM, Huo L, Tripathy D. Clinical and molecular characteristics of HER2-low/zero, early stage triple negative breast cancer. SABCS, 2022. PMID: None.
8. Damodaran S, Lu D, Schwartz-Gomez J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi M, Murthy RK, Moulder SL, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium 2022, 2022. PMID: None.
9. Murthy RK, O'Brien B, Berry DA, Monroe MG, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikanwa A, Ferguson S, deGroot JF, Krop I, Valero V, Mothaffar R, Wolff A, Tripathy D, Lin NU, Reasor E. Safety and Efficacy of a Tucatinib-Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis (LM) in HER2+ Breast Cancer: Results from TBCRC049, a Phase 2 Non-Randomized Study. SABCS 2021, 2021. PMID: None.
10. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Cameron D, Carey L, Chien AJ, Giuseppe C, DiGiovanna MT, Krop I, Loi S, Oibi S, Mueller V, Oliveira M, Slamon D, Wardley H, Zelnak A, Ramos J, Hortobagyi GN, Wentao F, Winder E. Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Previously Treated HER2+ Metastatic Breast Cancer with Brain Metastases (HER2CLIMB). SABCS 2021, 2021. PMID: None.
11. Kabraji S, Ni J, Sammons S, Pereslete A, Anders C, Hughes M, Murthy RK, Raghavendra A, Monroe M, Liangge H, ep W, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM). SABCS 2021, 2021. PMID: None.
12. Basho R, McArthur H, Mita M, Tighiouart M, McAndrew P, Park, Shio S, Burrison M, Mirhadi A, Knott S, Murthy RK, El-Masry M, Hu J, Rudnick S, Phuphanich S, Shi. Single Arm, Open Label Phase 1b/2 Study of Tucatinib in Combination with Pembrolizumab and Trastuzumab for patients with HER2+ Breast Cancer Brain Metastases. SABCS 2021 None(None):None, 2021. PMID: None.
13. Kamran A, Youngchul KL, DeJeses M, Beyer SJ, Woodhouse KD, Murthy RK, Li J, Armaghani AJ, Arrington JH, Costa RL, Czermiech BJ, Etame HB, Forsyth PA, Khong HT, Oliver DE, Rosa M, Sahebjam S, Soliman HH, Sovano AE, Vogelbaum MA, Yu M, Han HS. Phase I/II study of stereotactic radiation and abemaciclib in the management of hormone receptor positive HER2 negative breast cancer brain metastases. SABCS 2021, 2021. PMID: None.
14. Bachelot T, Lin NU, Murthy RK, s H, Borges V, Oliveira M, Oakman C, Khan S, Lynch C, Westbrook K, Doyle C, Reinish M, Colleoni M, Slamon D, Hortobagyi GN, Winer EP, McGoddrick S, Fend W, Loibl S. Impact of Tucatinib on Progression Free Survival in Patients with HER2+ Metastatic Breast Cancer and Brain Metastases. ESMO 2021, 2021. PMID: None.
15. Abuhadra N, Chang CC, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). ASCO 2021, 2021. PMID: None.
16. Curigliano G, Mueller V, Borges V, Hamtton E, Hurvitz S, Lor S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi G, Krop I, Loch S, Pegrem M, Slamon D, Ramos J, Zhang C, Winer E. Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases. ASCO 2021, 2021. PMID: None.
17. Stringer-Reasor EM, O'Brien, BJ, Topletz-Erickson A, White J, Lobbous M, Riley K, Childress J, Lamaster K, Melisko M, Morikawa A, de Groot JF, Krop I, Valero V, Rimaui M, Wolff A, Tripathy D, Lin NU, Murthy RK. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. ACSO 2021, 2021. PMID: None.
18. Shukla MA, Gutierrez Barrera A, Gruschkus SK, Layman RM, Murthy RK, Arun B. Characteristics of HER2/neu positive breast cancer among patients with and without germline BRCA mutations. San Antonio Breast Cancer Symposium, 2020. PMID: None.
19. Abuhadra N, Yam C, Sun R, Huo L, White J, Ravenberg E, Adrada B, Sahin A, Litton J, Lim B, Ueno NT, Tripathy D, Damodaran S, Murthy RK, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Lucci A, Mittendorf E, Moulder S, Chang J. Prospective evaluation of outcomes with neoadjuvant therapy (NAT) in patients with metaplastic (Mp) triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2020. PMID: None.
20. Abuhadra N, Chang C, Yam C, Sun R, Huo L, White J, Ravenberg EE, Litton J, Lim B, Ueno NT, Arun B, Tripathy D, Damodaran S, Murthy RK, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Mittendorf M, Moulder S, Jenq R. Prospective evaluation of the gut microbiome and response to neoadjvuant therapy (NAT) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2020. PMID: None.
21. O'Brien BJ, Murthy RK, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Nanda R, Park BH, Krop I, Lin NU, Wolff A, Forero-Torres A, Stringer-Reasor E. TBCRC049: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer. Society of Neuro-oncology (SNO), 2020. PMID: None.
22. Lim B, Seth S, Huo L, Layman R, Valero V, Thompson A, White J, Litton J, Damadaran S, Candelaria R, Arun B, Rauch G, Murthy R, Zhao L, Zhang J, Ding Q, Symmans WF, Ramirez D, Ibrahim N, Thomas P, Moulder S, Ueno NT. Comprehensive Profiling of Androgen Receptor-Positive (AR+) Triple-Negative Breast Cancer (TNBC) Patients Treated with Standard Neoadjuvant Therapy (NAT)+/- Enzalutamide. ASCO Virtual Annual Meeting 2020. e-Pub 2020. PMID: None.
23. Lin NU, Murthy RK, Anders C, Borges V, Hurvotz S Loi S, Abramson V, Bedard PC, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien AJ, )'Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An G, Winer EP. Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Previously Treated HER2+ Metastatic Breast Cancer with Brain Metastases (HER2CLIMB). ASCO Virtual Meeting 2020. e-Pub 2020. PMID: None.
24. Sl M, Bassett RL, White JB, Huo L, Damodaran S, Lim B, Ueno NT, Murthy RK, Arun B, Valero V, Tripathy D, Hortobagyi GN, Litton JK, Thompson AM, Mittendorf EM, Ravenberg E, Santiago L, Adrada BE, Candelaria RP, Rauch GM. Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). ASCO Virtual Annual Meeting 2020, 2020. PMID: None.
25. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada B, Mttendorf E, White J, Ravenberg E, Damodaran S, Candelaria R, Arun B, Ueno NT, Santiago L, Murthy RK, Ibrahim N, Symmans WF, Moulder S, Huo L. Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). ASCO Virtual Meeting 2020. e-Pub 2020. PMID: None.
26. Curigliano G, Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Lin N, Borges V, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Mueller V, Carey L, Loibl S, Feng W, Walker L, Winer E. Tucatinib vs Placebo added to Trastuzumab and Capecitabine in Previously Treated HER2+ Metastatic Breast Cancer with and without brain metastases (HER2CLIMB). ESMO Breast 2020 Virtual Meeting, 2020. e-Pub 2020. PMID: None.
27. Abuhadra N, Sun R, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada B, Mttendorf E, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Murthy RK, Ibrahim N, Aysegul S, Moulder S, Huo L. The Immunomodulatory Subtype (IM) Enhances Prediction of Pathologic Complete Response (pCR) to Neoadjuvant Therapy (NAT) in Triple Negative Breast Cancers (TNBC) with Moderate Stromal Tumor Infiltrating Lymphocytes (STIL). ESMO Breast 2020 Virtual Meeting, 2020. e-Pub 2020. PMID: None.
28. Garber H, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy RK, Tripathy D, Piwnica-Worms H, Symmans F, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). San Antonio Breast Cancer Symposium. e-Pub 2019. PMID: None.
29. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz A, Lin NU, Borges V, Abramson VG, Anders C, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Mueller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey L, Curigliano G, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer E. Tucatinib vs Placebo with Capecitabine and Trastuzumab for Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB). San Antonio Breast Cancer Symposium. e-Pub 2019. PMID: None.
30. Murthy RK, O'Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park D, Park BH, Krop I, Lin NU, Wolff A, Forero-Torres A, Stringer-Reasor E. TBCRC049: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer. San Antonio Breast Cancer Symposium. e-Pub 2019. PMID: None.
31. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada B, White J, Ravenberg EE, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy RK, Ibrahim N, Sahin AA, Symmans WF, Moulder S, Huo L. Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium. e-Pub 2019. PMID: None.
32. Li J, Lang F, Guha N, Weinberg J, Rao G, Heimberger A, Yeboa DN, Chung C, McAleer MF, Davies M, Glitza I, Murthy RK, Rodon J, O'Brien B, Dumbrava E, Vining D, Schomer D, Sawaya R, Yung A, Wang Y, Suki D, Wozny M, Zaebst D, Nguyen A, Burton E, Davis S, Tawbi H. Establishment of a multidisciplinary brain metastasis clinic to improve centralized patient care and to faciiltate coordinated research effort. Society of Neuro-Oncology: Brain Metastases Conference, 2019. PMID: None.
33. Sinicrope K, Walker BP, Tremont I, Groves M, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Padro M, Matsuoka CK, Harrison R, Tummala S, Trevino C, Peinado S, Murthy RK, Liu D, Seeyedeh D, DeGroot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Society of Neuro-Oncology: Brain Metastases Conference, 2019. PMID: None.
34. Trevina CR, Murthy RK, Raghavendra AS, Loghin M, Seligman C, Ferguson SD, Matsuoka CK, Harrison R, Sinicrope KD, Valero V, Tripathy D, Tummala S, Hess K, de Groot J, O'Brien BJ. Intrathecal trastuzumab plus/minus IT topotecan for patients with HER2+ breast cancer and leptomeningeal metastasis. Society of Neuro-Oncology: Brain Metastases Conference, 2019. PMID: None.
35. Yang W, Santiago L, Murthy RK, Sahin A, Symmans WF, Moulder S, Ueno N, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. American Society of Clinical Oncology, 2019. PMID: None.
36. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. American Society of Clinical Oncology, 2019. PMID: None.
37. Sinicrope K, Murthy RK, Barata P, Walker J, Tremont-Lukats IW, Groves MD, Loghin M, Seligman C, Ferguson SD, Weathers SP, Penas-Prado, Matsuoka CK, Harrison R, Tummala S, Trevino CR, Peinado S, Seyedeh D, de Groot J, O'Brien B. Intrathecal Topotecan for Leptomeningeal Metastasis in Solid Tumors: The MD Anderson Experience. Brain Metastases Research Symposium: From Basic Science to Clinics - Vienna, Austria, 2019. PMID: None.
38. Campf J, Clifton GT, Hale DF, Vreeland TJ, Hickerson A, Holmes JP, Litton JK, Murthy RK, Lukas JJ, Mittendorf EA, Peoples GE. Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence. American Society of Clinical Oncology, 2019. PMID: None.
39. Paplomata E, Bachelot T, Meuller V, Murias C, Murthy RK, Okines AFC, Wardley AM, Walker L, Oliveira AM. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). European Society of Medical Oncology Breast Cancer. e-Pub 2019. PMID: None.
40. Campf J, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Holmes JP, Litton JK, Murthy R, Lukas J, Mittendorf EA, Peoples GE. Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence. American Society of Clinical Oncology, 2019. PMID: None.
41. Hickerson A, Clifton G, Hale DF, Peace KM, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Lukas JJ, Mittendorf EA, Peoples GE. Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial. ASCO-SITC Clinical Immuno-Oncology Symposium, 2019. PMID: None.
42. Murthy RK, Raghavendra AS, Hess K, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez Mac Gregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. San Antonio Breast Cancer Symposium. e-Pub 2018. PMID: None.
43. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. San Antonio Breast Cancer Symposium. e-Pub 2018. PMID: None.
44. Kida K, Lee J, Liu H, Lim B, Murthy RK, Sahin A, Lee C, Tripathy D, Ueno NT. Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab. San Antonio Breast Cancer Symposium. e-Pub 2018. PMID: None.
45. Clifton GT, Kemp-Bohan P, Hale DF, Myers JW, Brown TA, Holmes JP, Vreeland TJ, Litton JK, Murthy RK, Mittendorf EA, Peoples GE. Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients. San Antonio Breast Cancer Symposium. e-Pub 2018. PMID: None.
46. Modi S, Tsurutani J, Tamura K, Park H, Sagara Y, Murthy RK, Iwata H, Krop IE, Doi T, Redfern C, Moreno-Aspitia A, Redmen R, Lee C, Sugihara M, Fujisaki Y, Takahashi S. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study. San Antonio Breast Cancer Symposium. e-Pub 2018. PMID: None.
47. Litton JK, Molder S, Hess KR, Damodaran S, Rauch GM, Candelaria R, Adrada BE, Symmans WF, Murthy RK, Helgason T, Clayborn AR, Prabhakaran S, Valero V, Thompson AM, Mittendorf EA. Triple-Negative First-Line Study: Neoadjuvant Trial of nab-paclitaxel and Atezolizumab, a PD-L1 inhibitor, in patients with Triple Negative Breast Cancer (TNBC). European Society for Medical Oncology (ESMO). e-Pub 2018. PMID: None.
48. Yam C, Seth S, Hess KR, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Chang JT, Moulder SL. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy in metaplastic breast cancer. European Society of Medical Oncology (ESMO). e-Pub 2018. PMID: None.
49. Meric-Bernstam F, Beeram M, Mayordomo J, Hanna D, Ajani J, Murphy MB, Murthy RK, Piha-Paul S, Bauer T, Bendell J, El-Khoueiry A, Lenz H, Press M, Royer N, Hausman D, Hamilton E. Single Agent Activity of ZW25, a HER2 Targeted Bispecific Antibody, in Heavily Pretreated HER2 Expressing Cancers. American Society of Clinical Oncology. e-Pub 2018. PMID: None.
50. Litton JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, Desnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, Arun B. Neoadjuvant Talazoparib (TALA) for Operable Breast Cancer Patients with a BRCA Mutation (BRCA+). American Society of Clinical Oncology. e-Pub 2018. PMID: None.
51. Iwata H, Tamura K, Toshihiko D, Tsurutani J, Modi S, Park H, Krop I, Sagara Y, Redfern C, Murthy RK, Redman R, Shitara K, Fujisaki Y, Sugihara M, Zhand L, Shahidi J, Yver A, Takahashi S. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing advanced solid tumors: Long-term efficacy and safety from a first-in-human phase 1 study with multiple expansion cohorts. American Society of Clinical Oncology. e-Pub 2018. PMID: None.
52. Moulder SL, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, Thompson AM, Lim B, Mittendorf EA, Litton JK, Symmans WF. Precision neoadjuvant therapy (P-NAT): a planned interim analysis of A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS). American Society of Clinical Oncology. e-Pub 2018. PMID: None.
53. Yam C, Hess KR, Litton JK, Yang W, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas E, Lane DL, Rauch GM, Adrada BE, Gilcrease MZ, Moulder SL. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). American Society of Clinical Oncology, 2018. PMID: None.
54. Murthy RK, Hamilton E, Ferrario C, Aucoin N, Falkson C, Chamberlain M, Gray T, Borges V. Clinical Benefit of Tucatinib after Isolated Brain Progression: A Retrospective Pooled Analysis of Tucatinib Phase 1b Studies in HER2+ Metastatic Breast Cancer. American Society of Clinical Oncology. e-Pub 2018. PMID: None.
55. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. American Society of Clinical Oncology. e-Pub 2018. PMID: None.
56. Oikawa M, Ramesh N, Sei E, Bai S, Murthy RK, O’Brien BJ, Navin NE. Noninvasive genomic profiling of cerebral spinal fluid in breast cancer patient with leptomeningeal disease. American Association for Cancer Research. e-Pub 2018. PMID: None.
57. Rauch G, Zhu H, Li H, Adrada B, Santiago L, Candelaria R, Wang H, Leung J, Litton J, Wu Y, Murthy RK, Mittendorf E, Yang W. Association of quantitative MRI features with tumor infiltrating lymphocytes and treatment response prediction in HER2 positive subtype of breast cancer. San Antonio Breast Cancer Symposium, 2017. PMID: None.
58. Murthy RK, Raghavendra AS, Hess KR, Hong AZ, Lim B, Barcenas CH, Chavez-MacGregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson A, Valero V, Tripathy D, Ueno NT. Patterns of use and effectiveness of neoadjuvant pertuzumab-containing regimens in stage II-III HER2-neu positive breast cancer: a retrospective, single institutional experience. San Antonio Breast Cancer Symposium, 2017. PMID: None.
59. Yam C, Santiago L, Candelaria R, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno N, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Symmans WF, Moulder SL, Yang W. Risk of Needle-Track Seeding with Serial Ultrasound Guided Biopsies in Triple Negative Breast Cancer (TNBC). San Antonio Breast Cancer Symposium, 2017. PMID: None.
60. Bashour SI, Ibrahim NK, Schomer DF, Colen RR, Sawaya R, Suki D, Rao G, Murthy RK, Moulder SL, Abugabal Y, Hess KR, Fuller GN. Central nervous system miliary metastasis in breast cancer patients. San Antonio Breast Cancer Symposium, 2017. PMID: None.
61. Yee D, DeMichele A, Isaacs C, Symmans F, Yau C, Albain KS, Hylton NM, Forero-Torres A, van't Veer LJ, Perlmutter J, Rugo HS, Melisko M, Y-Y C, Balassanian R, Krings G, Datnow B, Hasteh F, Tipps A, Weidner N, Zhang H, Tickman R, Thornton S, Ritter J, Amin K, Klein M, Chen B, Keeney G, Ocal T, Feldman M, Klipfel N, Sattar H, Mueller J, Gwin K, Baker G, Kallakury B, Zeck J, Duan X, Ersahin C, Gamez R, Troxell M, Mansoor A, Grasso LeBeau L, Sams S, Wisell J, Wei S, Harada S, Vinh T, Stamatakos MD, Tawfik O, Fan F, Adams A, Rendi M, Minton S, Magliocco A, Sahoo S, Fang Y, Hirst G, Singhrao R, Asare SM, Wallace AM, Chien AJ, Ellis ED, Han HS, Clark AS, Boughey JC, Elias AD, Nanda R, Korde L, Murthy RK, Lang J, Northfelt D, Khan Q, Edmiston KK, Viscusi R, Haley B, Kemmer K, Zelnak A, Berry DA, Esserman LJ. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. San Antonio Breast Cancer Symposium, 2017. PMID: None.
62. Hamilton E, Murthy RK, Ferrario C, Conlin A, Krop I, Falkson C, Qamar K, Chamberlain M, Gray T, Borges V. Prolonged progression-free survival (PFS) in advanced HER2+ metastatic breast cancer with or without brain metastases: a pooled analysis of tucatinib phase Ib studies. San Antonio Breast Cancer Symposium, 2017. PMID: None.
63. Yam C, Huo L, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno N, Lim B, Murthy RK, Damodaran S, Helgason MS, Thompson AM, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans WF, Gilcrease MZ, Moulder SL. Androgen Receptor Positivity is Associated with Nodal Disease in Triple Negative Breast Cancer. San Antonio Breast Cancer Symposium, 2017. PMID: None.
64. Hamilton E, Meric-Bernstam F, Infante J, Murthy RK, Patnaik A, Piha-Paul SA, Tolcher A, Hausman D, Royer N, Beeram M. Phase 1 dose escalation with ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-high breast cancer (BC). San Antonio Breast Cancer Symposium, 2017. PMID: None.
65. Murthy RK, Fujii T, Hess K, Raghavendra AS, Lim B, Barcenas CH, Zhang HA, Chavez Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson A, Valero V, Tripathy D, Ueno NT. Neoadjuvant pertuzumab-containing regimens improve pathologic complete response rates in stage II-III HER2-neu positive breast cancer: a retrospective, single institutional experience. American Society of Clinical Oncology, 2017. PMID: None.
66. Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Bega T, Barcenas C, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai, Murthy RK. Long-term Survival of De Novo Stage IV Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers treated with HER2 Targeted Therapy. American Society of Clinical Oncology, 2017. PMID: None.
67. Pant S, Wheler JJ, Fu S, Hong DS, Karp DD, Subbiah V, Tsimberidou AM, Holley VR, Brewster AM, Koenig KH, Ibrahim NK, Murthy, RK, Meric-Bernstam F, Janku F. Proof-of Concept Phase I Study of Everolimus, Letrozole and Trastuzumab in Hormone Receptor-Positive HER2-Positive/Amplified or Mutant Metastatic Breast Cancer or other Solid Tumors: Evaluating Synergy and Overcoming Resistance. American Society of Clinical Oncology, 2017. PMID: None.
68. Yam C, Hess KR, Litton JK, Yang W, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Gilcrease MZ, Santiago L, Candelaria RP, Rauch GM, Adrada BE, Symmans F, Moulder SL. A Randomized, Triple Negative Breast Cancer Enrolling Trial to Confirm Molecular Profiling Improves Survival (ARTEMIS). American Society of Clinical Oncology, 2017. PMID: None.
69. Johnson GL, Angus S, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher KK, Forero A, Krop IE, Thompson AM, Murthy RK, He X, Perou CM, Earp S, Carey LA. Window-of-Opportunity Clinical Trial Reveals Adaptive Kinome Reprogramming in Single and Combination HER2-Targeting in Breast Cancer (BrCa). American Society of Clinical Oncology, 2017. PMID: None.
70. Zhao M, Scott S, Evans K, Yuca E, Murthy RK, Abodadri-Connors F, Cutler R, Lalani AS, Piha-Paul S, Meric-Bernstam F. Exploring optimal targeted combination therapies with neratinib for HER2 breast cancer. American Association for Cancer Research, 2017. PMID: None.
71. Peace KM, Litton JK, Murthy RK, Vreeland TJ, Hale DF, Jackson DO, Berry JS, Trappey AF, Herbert GS, Clifton GT, Hardin MO, Peoples GE, Mittendorf EA. Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + Neu Vax to prevent breast cancer recurrence in HER2+ breast cancer patients. American Association for Cancer Research, 2017. PMID: None.
72. Sinn BV, Tsai TH, Lau R, Fu C, Gould R, Murthy RK, King TA, Hatzis C, Kwiatkowski DN, Valero V, Symmans WF. SET4 Targeted RNA-seq Assay to Measure Activating ER Mutations and ER/PR-Associated Gene Expression To Predict Sensitivity To Endocrine Therapy for Metastatic Breast Cancer. American Association for Cancer Research, 2017. PMID: None.
73. Hamilton E, Borges V, Murthy RK, Anders C, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pivort X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). American Association for Cancer Research 77(4 Suppl), 2017. PMID: None.
74. Hamilton E, Borges V, Murthy RK, Anders C, Cameron D, Carey L, Muller V, Curigliano G, Gelmon, K, Hortobagyi G, Krop I, Loibl S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai, Winer E. A phase 2 randomized, double-blinded, controlled study of Tucatinib (ONT-380) vs. placebo in combination with Capecitabine and Trastuzumab in patients with pretreated HER2+unresectable locally advanced or metastatic breast carcinoma (HER2CLIMB). San Antonio Breast Cancer Symposium, 2016. PMID: None.
75. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Barcenas CH, Tripathy D, Berry D, Hortobagyi GN. Proposal for a new breast cancer staging classification: incorporating clinical and biologic factors. San Antonio Breast Cancer Symposium, 2016. PMID: None.
76. Hamilton E, Borges V, Conlin A, Walker L, Murthy RK, Moulder S. Efficacy results of a phase 1b study of ONT-380, an oral HER2 specific inhibitor, in combination with Capecitabine and Trastuzumab in HER2+ metastatic breast cancer with brain metastases. San Antonio Breast Cancer Symposium, 2016. PMID: None.
77. Baez-Vallecillo L, Raghavendra AS, Hess K, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib after pertuzumab and/or ado-trastuzumab emtansine in metastatic HER2-positive breast cancer. San Antonio Breast Cancer Symposium, 2016. PMID: None.
78. Sinn BV, Tsai TH, Lau R, Fu C, Gould R, Murthy RK, King TA, Hatzis C, Kwiatkowski DN, Valero V, Symmans WF. SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer. San Antonio Breast Cancer Symposium, 2016. PMID: None.
79. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Booser D, Schwartz-Gomez J, Mills GB, Piwnica-Worms H, Arun BA. A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. European Society of Medical Oncology, 2016. PMID: None.
80. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Pusztai L, Murthy RK. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab. American Society of Clinical Oncology, 2016. PMID: None.
81. Lim B, Murthy RK, Jackson S, Willey J, Lee J, Alvarez R, Barcenas C, Ibrahim N, Karuturi M, Booser D, Moulder S, Giordano S, Brewster A, Walters R, Brown P, Tripathy D, Valero V, Ueno NT. Open-label phase 1b study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab. American Society of Clinical Oncology, 2016. PMID: None.
82. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. American Association for Cancer Research, 2016. PMID: None.
83. Murthy RK, Welch S, Chaves J, Walker L, Krop I, Hamilton E, Borges. ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). San Antonio Breast Cancer Symposium, 2015. PMID: None.
84. Lim B, Jackson S, Willey J, Murthy RK, Booser D, Giordano S, Ibrahim N, Barcenas C, Brewster A, Walters R, Brown P, Alvarez R, Tripathy D, Valero V, Ueno N. A single-center, open-label phase 1b study of entinostat in patients with HER2+ locally recurrent or metastatic breast cancer in whom trastuzumab had failed at The University of Texas MD Anderson Cancer Center. San Antonio Breast Cancer Symposium, 2015. PMID: None.
85. Albain KS, Leyland-Jones B, Symmans F, Paoloni M, van't Veer L, Yau C, Chien AJ, Wallace A, Forero-Torres A, Yee D, Kaplan H, Nanda R, Moulder S, Haley B, Elias A, Boughey J, Lang J, DeMichele A, Isaacs C, Kemmer K, Godellas C, Buxton M, Hogarth M, Hylton N, Perlmutter J, Edmiston K, KIorde L, Viscusi R, Khan Q, Northfelt D, Alvarado M, Melisko M, Schwab R, Helsten T, Krontiras H, Beckwith H, Ellis ED, Jaskowiak N, Murthy RK, Unni N, Haddad T, Tripathy D, Russel K, Clark A, Clennel JL, Sanil A, Berry D, Esserman L. The evaluation of Trebananib plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial. San Antonio Breast Cancer Symposium, 2015. PMID: None.
86. Murthy RK, Symmans WF, Litton JK, Arun BK, Ibrahim NK, Alvarez RH, Gilcrease MZ, Valero V, Tripathy D, Moulder SL. Phase II single arm study of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium, 2014. PMID: None.
87. Moulder-Thompson SL, Yang W, Ueno NT, Ensor J, Valero V, Alvarez R, Litton JK, Murthy RK, Ibrahim N, Arun B, Mittendorf B, Hunt K, Meric-Bernstam F, Piwnica-Worms H, Candelaria R, Tripathy D, Symmans F. Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy. San Antonio Breast Cancer Symposium, 2014. PMID: None.
88. Murthy RK, Ferguson SE, Tereffe W, Bedrosian I, Moulder SL. A new model for multidisciplinary breast cancer care improves resource utilization, patient retention, and clinical trial enrollment at an academic breast center. ASCO Breast Cancer Symposium, 2014. PMID: None.
89. Murthy RK, Chen H, Jackson MA, Woodson AH, Profato JL, Litton JK, Arun BA, Valero V, Barcenas CH. Genetic testing referral patterns and clinical outcomes among high-risk breast cancer survivors. American Society of Clinical Oncology 32(15), 2014. PMID: None.
90. Murthy RK, Schover LR, Theriault RL, Valero V, Woodard TL, Hodge S, Litton JK. Women with pregnancy associated early breast cancer achieve improved emotional well-being as a result of their cancer experience. San Antonio Breast Cancer Symposium, 2013. PMID: None.
91. Murthy RK, Varma A, Mishra P, Hess KR, Young EJ, Murray JL, Koenig KH, Green MC, Moulder SL, Melhem-Bertrandt A, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. American Society of Clinical Oncology 30(15), 2012. PMID: None.
92. Murthy RK, Kvale EA, Lee JY, Taylor R, Nabors LB. Distress and quality of life in neuro-oncology patients. Supportive Oncology Conference 5(8):407, 2007. PMID: None.
93. Kvale EA, Andea, Murthy RK, Jahraus C. Pseudosclerodermatous panniculitis as a cutaneous manifestation in palliative care. Supportive Oncology Conference 5(8):406, 2007. PMID: None.
94. Christein JD, Leeth RR, RK M, Heslin M, Jhala NC, Arnoletti P, Vickers SM. Does margin status affect outcome after pancreaticoduodenectomy for pancreatic adenocarcinoma. Alabama Chapter of the American College of Surgeons, 2006. PMID: None.
95. Christein JD, Leeth RR, Murthy RK, Heslin MR, Jhala NC, Arnoletti JP, Vickers SM. Biological markers as predictors of outcome and margin status for pancreatic adenocarcinoma after pancreaticoduodenectomy. Congress of the American Hepato-Pancreato-Biliary Association, 2006. PMID: None.
96. Gouda MA, Gonugunta A, Dumbrava E, Yap TA, Rodon J, Piha-Paul SA, Pohlmann P, Damodaran S, Murthy RK, Valero V, Mouabbi J, Tripathy D, Sahin A, Chen H, Meric-Bernstam F. HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. SABCS. PMID: None.
97. Li J, Otte H, Raso MG, Barrientos Toro E, Batra H, Tang X, Mendoza Perez J, Schwartz Gomez J, Karuturi MS, Stauder MC, Damodaran S, Litton JK, Murthy RK, Haymaker C. Exploration of the circulating immune microenvironment stratified by breast cancer subtype. SITC. PMID: None.

Book Chapters

1. Tripathy D, Makhnoon S, Arun B, Sahin A, Kettner NM, Damodaran S, Keyomarsi K, Yang W, Hunt KK, Clemens M, Woodward WA, Mitchell MP, Layman R, Hobbs EA, Lim B, Dupuis M, Murthy RK, Alhalabi O, Ibrahim N, Subbiah IS, Barcenas C. Neoplasms of the Breast. In: Holland-Frei Cancer Medicine. 10. Wiley Blackwell, 1361-1412, 2023.
2. Al-Awadhi A, Murthy RK, Recht A. Breast Cancer Overview. In: Clinical Radiation Oncology. 5th. Elsevier, 1297-1316, 2020.
3. Murthy, RK, Valero V. Overview of systemic therapy for breast cancer. In: Textbook of general surgical oncology. 1st. The McGraw-Hill Companies, Inc, 2018.
4. Murthy RK, Valero V, Buchholz TA. Breast Cancer. In: Clinical Radiation Oncology. 4th. Elsevier, 1284, 2015.
5. Murthy RK, Morrow PK. Breast Cancer in Young Women. In: Advanced Therapy of Breast Disease 3rd Edition. 3rd. People's Medical Publishing House, 1203, 2012.